The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease
- Autores
- Higa, Leticia Herminia; González Epelboim, Victoria Rebeca Dana; Ghosal, Kajal; Perez, Ana Paula; Altube, María Julia; Morilla, María José; Romero, Eder Lilia
- Año de publicación
- 2025
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Dry eye disease (DED), the most prevalent ocular surface disorder worldwide, is currently treated with topical formulations for hydration, lubrication, or anti-inflammatory action. Due to natural barriers of the ocular surface, which limit retention and penetration of exogenous materials, the local bioavailability of topical formulations is minimal. Lipid-based nanomedicines are the most accepted nanomedicines by the pharmaceutical industry and regulatory agencies. Evaporative DED cases could benefit from topical mucoadhesive or mucopenetrating lipid-based ophthalmic nanomedicines (LBON). Besides lubricating and restoring the lipid film, topical nanomedicines offer site-specific drug delivery, magnified targeted intracellular delivery, and reduced systemic drug distribution. The resultant reduced dosing frequency may improve patients' adherence to chronic treatments. To treat DED, however, LBON must not interfere with vision or irritate, and their chemical composition, osmolarity, viscosity, pH, and refractive index must be properly selected /adjusted. Importantly, pharmacokinetics and pharmacodynamics of nanomedicines depend on the techniques used to produce each nanoparticulate structure. Hence, the structural features and resultant activities of nanomedicines prepared at lab scale, differ from those being manufactured at larger industrial scales. Due to ethical and economic reasons, preclinical assessment of LBON should therefore be performed using in vitro disease models. Here, the preclinical performances of LBON reported over the past 10 years, are critically examined. Overall, to become more significant and predictable, further preclinical developments of LBON need to become more technically rigorous and include the help of more sophisticated and broadly available in vitro models.
Fil: Higa, Leticia Herminia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: González Epelboim, Victoria Rebeca Dana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Ghosal, Kajal. Jadavpur University; India
Fil: Perez, Ana Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Altube, María Julia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Morilla, María José. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina
Fil: Romero, Eder Lilia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina - Materia
-
LIPID BASED-NANOMEDICINES
DRY EYE DISEASE
IN VITRO MODELS
OPHTALMIC - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/271137
Ver los metadatos del registro completo
id |
CONICETDig_c4bd9d02a9ac1352f3eed4f3481975ec |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/271137 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye diseaseHiga, Leticia HerminiaGonzález Epelboim, Victoria Rebeca DanaGhosal, KajalPerez, Ana PaulaAltube, María JuliaMorilla, María JoséRomero, Eder LiliaLIPID BASED-NANOMEDICINESDRY EYE DISEASEIN VITRO MODELSOPHTALMIChttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Dry eye disease (DED), the most prevalent ocular surface disorder worldwide, is currently treated with topical formulations for hydration, lubrication, or anti-inflammatory action. Due to natural barriers of the ocular surface, which limit retention and penetration of exogenous materials, the local bioavailability of topical formulations is minimal. Lipid-based nanomedicines are the most accepted nanomedicines by the pharmaceutical industry and regulatory agencies. Evaporative DED cases could benefit from topical mucoadhesive or mucopenetrating lipid-based ophthalmic nanomedicines (LBON). Besides lubricating and restoring the lipid film, topical nanomedicines offer site-specific drug delivery, magnified targeted intracellular delivery, and reduced systemic drug distribution. The resultant reduced dosing frequency may improve patients' adherence to chronic treatments. To treat DED, however, LBON must not interfere with vision or irritate, and their chemical composition, osmolarity, viscosity, pH, and refractive index must be properly selected /adjusted. Importantly, pharmacokinetics and pharmacodynamics of nanomedicines depend on the techniques used to produce each nanoparticulate structure. Hence, the structural features and resultant activities of nanomedicines prepared at lab scale, differ from those being manufactured at larger industrial scales. Due to ethical and economic reasons, preclinical assessment of LBON should therefore be performed using in vitro disease models. Here, the preclinical performances of LBON reported over the past 10 years, are critically examined. Overall, to become more significant and predictable, further preclinical developments of LBON need to become more technically rigorous and include the help of more sophisticated and broadly available in vitro models.Fil: Higa, Leticia Herminia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: González Epelboim, Victoria Rebeca Dana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: Ghosal, Kajal. Jadavpur University; IndiaFil: Perez, Ana Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: Altube, María Julia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: Morilla, María José. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaFil: Romero, Eder Lilia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; ArgentinaElsevier2025-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/271137Higa, Leticia Herminia; González Epelboim, Victoria Rebeca Dana; Ghosal, Kajal; Perez, Ana Paula; Altube, María Julia; et al.; The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease; Elsevier; Journal of Drug Delivery Science and Technology; 9-2025; 1-541773-22472588-8943CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S1773224725008792info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jddst.2025.107476info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:15:31Zoai:ri.conicet.gov.ar:11336/271137instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:15:32.115CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease |
title |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease |
spellingShingle |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease Higa, Leticia Herminia LIPID BASED-NANOMEDICINES DRY EYE DISEASE IN VITRO MODELS OPHTALMIC |
title_short |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease |
title_full |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease |
title_fullStr |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease |
title_full_unstemmed |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease |
title_sort |
The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease |
dc.creator.none.fl_str_mv |
Higa, Leticia Herminia González Epelboim, Victoria Rebeca Dana Ghosal, Kajal Perez, Ana Paula Altube, María Julia Morilla, María José Romero, Eder Lilia |
author |
Higa, Leticia Herminia |
author_facet |
Higa, Leticia Herminia González Epelboim, Victoria Rebeca Dana Ghosal, Kajal Perez, Ana Paula Altube, María Julia Morilla, María José Romero, Eder Lilia |
author_role |
author |
author2 |
González Epelboim, Victoria Rebeca Dana Ghosal, Kajal Perez, Ana Paula Altube, María Julia Morilla, María José Romero, Eder Lilia |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
LIPID BASED-NANOMEDICINES DRY EYE DISEASE IN VITRO MODELS OPHTALMIC |
topic |
LIPID BASED-NANOMEDICINES DRY EYE DISEASE IN VITRO MODELS OPHTALMIC |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/2.10 https://purl.org/becyt/ford/2 |
dc.description.none.fl_txt_mv |
Dry eye disease (DED), the most prevalent ocular surface disorder worldwide, is currently treated with topical formulations for hydration, lubrication, or anti-inflammatory action. Due to natural barriers of the ocular surface, which limit retention and penetration of exogenous materials, the local bioavailability of topical formulations is minimal. Lipid-based nanomedicines are the most accepted nanomedicines by the pharmaceutical industry and regulatory agencies. Evaporative DED cases could benefit from topical mucoadhesive or mucopenetrating lipid-based ophthalmic nanomedicines (LBON). Besides lubricating and restoring the lipid film, topical nanomedicines offer site-specific drug delivery, magnified targeted intracellular delivery, and reduced systemic drug distribution. The resultant reduced dosing frequency may improve patients' adherence to chronic treatments. To treat DED, however, LBON must not interfere with vision or irritate, and their chemical composition, osmolarity, viscosity, pH, and refractive index must be properly selected /adjusted. Importantly, pharmacokinetics and pharmacodynamics of nanomedicines depend on the techniques used to produce each nanoparticulate structure. Hence, the structural features and resultant activities of nanomedicines prepared at lab scale, differ from those being manufactured at larger industrial scales. Due to ethical and economic reasons, preclinical assessment of LBON should therefore be performed using in vitro disease models. Here, the preclinical performances of LBON reported over the past 10 years, are critically examined. Overall, to become more significant and predictable, further preclinical developments of LBON need to become more technically rigorous and include the help of more sophisticated and broadly available in vitro models. Fil: Higa, Leticia Herminia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina Fil: González Epelboim, Victoria Rebeca Dana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina Fil: Ghosal, Kajal. Jadavpur University; India Fil: Perez, Ana Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina Fil: Altube, María Julia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina Fil: Morilla, María José. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina Fil: Romero, Eder Lilia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina |
description |
Dry eye disease (DED), the most prevalent ocular surface disorder worldwide, is currently treated with topical formulations for hydration, lubrication, or anti-inflammatory action. Due to natural barriers of the ocular surface, which limit retention and penetration of exogenous materials, the local bioavailability of topical formulations is minimal. Lipid-based nanomedicines are the most accepted nanomedicines by the pharmaceutical industry and regulatory agencies. Evaporative DED cases could benefit from topical mucoadhesive or mucopenetrating lipid-based ophthalmic nanomedicines (LBON). Besides lubricating and restoring the lipid film, topical nanomedicines offer site-specific drug delivery, magnified targeted intracellular delivery, and reduced systemic drug distribution. The resultant reduced dosing frequency may improve patients' adherence to chronic treatments. To treat DED, however, LBON must not interfere with vision or irritate, and their chemical composition, osmolarity, viscosity, pH, and refractive index must be properly selected /adjusted. Importantly, pharmacokinetics and pharmacodynamics of nanomedicines depend on the techniques used to produce each nanoparticulate structure. Hence, the structural features and resultant activities of nanomedicines prepared at lab scale, differ from those being manufactured at larger industrial scales. Due to ethical and economic reasons, preclinical assessment of LBON should therefore be performed using in vitro disease models. Here, the preclinical performances of LBON reported over the past 10 years, are critically examined. Overall, to become more significant and predictable, further preclinical developments of LBON need to become more technically rigorous and include the help of more sophisticated and broadly available in vitro models. |
publishDate |
2025 |
dc.date.none.fl_str_mv |
2025-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/271137 Higa, Leticia Herminia; González Epelboim, Victoria Rebeca Dana; Ghosal, Kajal; Perez, Ana Paula; Altube, María Julia; et al.; The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease; Elsevier; Journal of Drug Delivery Science and Technology; 9-2025; 1-54 1773-2247 2588-8943 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/271137 |
identifier_str_mv |
Higa, Leticia Herminia; González Epelboim, Victoria Rebeca Dana; Ghosal, Kajal; Perez, Ana Paula; Altube, María Julia; et al.; The crying game: Lipid-based ophthalmic nanomedicines, and in vitro models to test their performance against dry eye disease; Elsevier; Journal of Drug Delivery Science and Technology; 9-2025; 1-54 1773-2247 2588-8943 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S1773224725008792 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jddst.2025.107476 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614092198772736 |
score |
13.070432 |